TD Cowen analyst Phil Nadeau raised the firm’s price target on Vertex Pharmaceuticals to $350 from $330 and keeps an Outperform rating on the shares. The analyst said its pipeline is maturing toward notable events over the next year including the potential approval/launch of exa-cel and results from the pivotal trials of 548 and the vanza triple.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $385 from $339 at Guggenheim
- Vertex Pharmaceuticals price target raised to $325 from $280 at Baird
- Vertex Pharmaceuticals price target raised to $410 from $350 at Oppenheimer
- Vertex Pharmaceuticals price target raised to $380 from $326 at H.C. Wainwright
- Vertex Pharmaceuticals price target raised to $384 from $342 at Barclays
